- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer
The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.
Head and neck cancer is among the few solid tumors whose incidence is increasing in the United States. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUDC-101 with radiation and chemotherapy were reported by the University of Colorado Cancer Center and 6 other US cancer centers in the journal Clinical Cancer Research.
CUDC-101, currently being developed by Curis, Inc, works by inhibiting two growth factors and an enzyme that effects DNA expression—EGFR, Her2 and HDAC—all of which are overexpressed in many cancers, including the target of this trial: the common type of especially aggressive head and neck cancer that is not caused by the human papilloma virus (HPV-) but rather by tobacco or alcohol.
Link to the complete report in ScienceDaily:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
